Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD34+ enriched hematopoietic stem cells
- Development stage
- Phase 2
- Lead developer
- Vor Bio
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
CD34+ enriched hematopoietic stem cells are an investigational cell therapy product consisting of purified stem and progenitor cells derived from allogeneic donors. Developed and investigated by Dr. Guenther Koehne, these cells are processed using the CliniMACS system, which employs immunomagnetic beads to select for CD34+ cells while depleting T-cells from the graft. This T-cell depletion is intended to reduce the risk of graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies such as acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), and chronic myelomonocytic leukemia (CMML). By providing a highly enriched population of stem cells, the therapy aims to ensure rapid and sustained hematopoietic engraftment without the need for intensive pharmacological immunosuppression.
- Other names
- CD34+ enriched transplantsCliniMACS-processed CD34+ cellsCD34+ enriched stem cell transplantsT-cell depleted CD34+ enriched hematopoietic stem cells
Beyond the preview
Go deeper on CD34+ enriched hematopoietic stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD34+ enriched hematopoietic stem cells.